{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:21:37Z","timestamp":1792448497608,"version":"4.5.0"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Low adiponectin levels may contribute to insulin resistance. This first\u2010in\u2010human study evaluated adiponectin receptor agonist (PEG)\u2010BHD1028 in subjects with insulin resistance. Adults with BMI\u2009\u2265\u200927\u2009kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    , HOMA\u2010IR\u2009\u2265\u20091.8, and HbA1c\u2009&lt;\u20096.5% received subcutaneous injections of (PEG)\u2010BHD1028 or placebo in single\u2010ascending dose (SAD) cohorts (4, 8, 16, 32, and 64\u2009\u03bcg\/kg) and multiple\u2010ascending dose (MAD) cohorts for 28\u2009days (8, 16, and 32\u2009\u03bcg\/kg QD). Each cohort had eight subjects, with two on placebo. Area under the curve (AUC) was obtained for insulin c\u2010peptide, insulin, and glucose in a mixed meal tolerance test (MMTT) at Day \u22121 and Day 28. Body weight, triglycerides, and inflammatory markers were measured at regular intervals. Changes were analyzed by the Kruskal\u2013Wallis test (for MMTT) and generalized estimating equations (GEEs). The MAD cohort mean age was 49\u2009years, with a body mass index of 32, baseline HOMA\u2010IR 3.8, and 42% female. Mild gastrointestinal adverse events occurred on (PEG)\u2010BHD1028 (50%) and placebo (33%) without discontinuations. Drug exposure was proportional to dose. Insulin c\u2010peptide AUC changes were +25% on placebo and \u221263%, + 24%, and +\u20092% on (PEG)\u2010BHD1028 8, 16, and 32\u2009\u03bcg\/kg doses (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Reductions in insulin (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.116) were also observed, with the greatest percentage change on 8\u2009\u03bcg\/kg. There were no consistent differences between groups in body weight, triglycerides, and inflammatory markers. Adiponectin agonist (PEG)\u2010BHD1028 was well\u2010tolerated with dose\u2010related increases in exposure. Observed effects on insulin c\u2010peptide and insulin during the MMTT support further development.\n                  <\/jats:p>","DOI":"10.1111\/cts.70596","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T14:35:04Z","timestamp":1780756504000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Randomized, Double\u2010Blind, Placebo\u2010Controlled Phase 1 Study of Adiponectin Agonist (\n                    <scp>PEG<\/scp>\n                    )\u2010\n                    <scp>BHD1028<\/scp>\n                    in People With Insulin Resistance"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0704-0251","authenticated-orcid":false,"given":"Pablo","family":"Lapuerta","sequence":"first","affiliation":[{"name":"Lapuerta Consulting LLC  Skillman New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7584-2892","authenticated-orcid":false,"given":"Brian B.","family":"Kim","sequence":"additional","affiliation":[{"name":"EncuraGen Inc.  Anyang Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Obesity and Overweight","author":"World Health Organization","year":"2023"},{"key":"e_1_2_10_3_1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2021"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(21)00113\u20103"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12255-6"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-802385-3.00004-8"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2005\u20100005"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061321"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00539"},{"key":"e_1_2_10_10_1","unstructured":"ClinicalTrials.gov \u201cPhase 1\/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease \u201daccessed September 28 2025 https:\/\/www.clinicaltrials.gov\/study\/NCT04201574?intr=ALY688%20Ophthalmic%20Solution&rank=1&tab=results."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199256"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020884"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.877696"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743\u20107075\u20107\u201026"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12159"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.33.5.486"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI10761"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2005.03.008"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/21623945.2020"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107555"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70596","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70596","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:54:15Z","timestamp":1782104055000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/cts.70596"],"URL":"https:\/\/doi.org\/10.1111\/cts.70596","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70596"}}